

GLG Pharma, LLC
Developing the next generation of targeted therapies
- Stage Full Product Ready
- Industry Biotechnology
- Location Jupiter, FL, USA
- Currency USD
- Founded May 2009
- Employees 7
- Website glgpharma.com
Company Summary
GLG Pharma, LLC, is developing a series of inhibitors of activated (STAT3) protein covered by issued or pending patents, and licensed from the Moffitt Cancer Center & Research Institute, Tampa FL. GLG Pharma’s therapeutics will treat a wide variety of STAT3 mediated diseases; cancers ($75-80 billion by 2012); psoriasis ($7.3B) with potentially greater efficacy and fewer side effects than existing therapies.
Team
-
Hector J. Gomez, MD, PHDChief Executive Officer & Founder
Managed the development of several drugs, 10 of them currently in the market. Examples of major NDA’s are Enalapril (Vasotec) and Lisinopril (Prinivil/Zestril).
• President and CEO, Transcend Therapeutics, Inc.,
• VP of Medical Affairs, Vertex Pharmaceuticals
• Executive Director, Novartis
• Director and Senior Director, Merck/MSDRL Corporation
• Chairman, DNAPrint Genomics, Inc.
• Scientific Advisor, Athena Capital Partners, Inc. -
Richard Gabriel, MBAChief Operating Officer & Founder
Was instrumental in closing and managing over $135 million in contract revenue for Pharm-Eco Laboratories
• CEO & President of Calix Corporation, parent company to Pharm-Eco Laboratories, Inc.
• Successfully completed the formation of several genetics, chemistry and pharma JVs, LLCs & spin-offs
• CEO & President, DNAPrint Genomics, Inc.
• Assisted in the development of: Amprenavir, Emtricitabine, Altretamine, Zalcitabine
• Over 30 IND’s/AND -
Michael W. Lovell, PhDExecutive Vice President & Founder
Assisted over 28 clients with development and commercialization of over 30 products
• Founder & President, AcraPharm Consulting, Inc., providing CMC management and technical consulting services to pharmaceutical and bio-tech companies.
• Co-founder and VP, BioDevelopment Laboratories (BDL)
• Held several key executive and scientific positions at companies such as Arthur D. Little, Abbott Laboratories, G. D. Searle and Bristol-Myers. -
Sunanda Singh, MD, PhDDirector of Cancer Immunology
• Residency, General Surgery and Plastic and Reconstructive Surgery
• Private practice for over ten years
• Advisory Board of Hernando Healthcare Inc.
• Chief of Staff, Brooksville Regional Hospital and Spring Hill Regional Hospital
• Clinical interest: skin cancers, melanoma, reconstructive surgery, hand surgery, and wound healing
• Research interest: include tumor immunology, cancer biology, and transplantation immunology -
John J. Whalen, MDChief Medical Officer
Had overall responsibility or played major role in planning, execution and submission of development programs of eleven approvable NDAs or PLAs.
• SVP Clinical Research, SCIREX CRO
• SVP R&D, Alpha Therapeutics
• VP, Clinical Research at the GHBA (Now Covance)
• VP, Clinical Development Operations at Medimmune (Division of Astra Zeneca)
• Director, Clinical Research, MSDRL -
Ray Johnson, MBAChief Financial Officer (acting)
Held positions of CFO/ President with 5 early stage companies in the medical/pharmaceutical industry
• Has successfully raised over $30M of pre-venture capital for those companies
• Co-founder/President, Cytonics Corp.
• President, Atlas Spine, a spine implant company
• Founder/President of Doyen Medipharm,
• Vice Chairman of Jupiter’s Economic Development Advisory Board
• Chairman of the Early Stage Biotech Coalition
Advisors
-
McNamara & Carver, P.A.LawyerUnconfirmedHanna, Lemar & Morris, CPA's, PAAccountantUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.